Drugs / Muscimol
Muscimol
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00921128 | Jun 2009 → Sep 2016 | Parkinson disease | National Institute of Neurological Disorders and Stroke (NINDS) | Withdrawn | No outcome recorded |
| Phase 1 | NCT00005925 | Jun 2000 → Dec 2014 | epilepsy | National Institute of Neurological Disorders and Stroke (NINDS) | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Muscimol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005925 ↗ |
| Known as | Agarin | ChEMBL registry synonym — accepted as the source's own label CHEMBL273481 ↗ |
| Known as | MUSCIMOL HYDROBROMIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL273481 ↗ |
| Known as | NSC-333569 | ChEMBL registry synonym — accepted as the source's own label CHEMBL273481 ↗ |
| Known as | Pantherine | ChEMBL registry synonym — accepted as the source's own label CHEMBL273481 ↗ |
| Action | Activate | “muscimol, a neurotransmitter (gamma-aminobutyric acid, GABA) receptor agonist that suppresses neuronal activity” NCT00005925 ↗ |
| Modality | Small molecule | — CHEMBL273481 ↗ |
| Route | Other | “infused directly into the epileptic focus” NCT00005925 ↗ |